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Abstract 
 The improvement in histological diagnostic tools, including 
neuroendocrine markers by immunohistochemistry (IHC), has led to an 
increased recognition of pulmonary neuroendocrine tumors. This may 
explain their rapid increase in incidence, representing roughly 30% of all 
neuroendocrine tumors. NETs represent about 3% of all lung cancers. The 
incidence of pulmonary NETs is low, although reported to have increased 
over the past 30 years. According to the surveillance, epidemiology and end 
results program (SEER) database from 2003, the combined incidence has 
been 1.57/100 000 inhabitants. The median age at diagnosis for bronchial 
NETs is 64 years and for thymic NETs 59 years. The main therapy for 
bronchial NETs is surgical resection. The surgical approach is dependent on 
the size, location and tissue type. Bronchoscopic laser excision of 
intraluminal typical bronchial NETs should be considered a suboptimal 
treatment and reserved for inoperable patients or performed as preoperative 
disobliterating procedure. Cytotoxic treatment combined with surgical 
resection when indicated has been the standard for metastatic bronchial and 
thymic NETs, although the available chemotherapy regimens demonstrate a 
rather poor effect. Chemotherapy for small-cell lung cancer (SCLC), which 
is a chemosensitive but not curable cancer, is discussed in the appropriate 
guidelines.  
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Introduction: 
 The improvement in histological diagnostic tools, including 
neuroendocrine markers by immunohistochemistry (IHC), has led to an 
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increased recognition of pulmonary neuroendocrine tumors. This may 
explain their rapid increase in incidence, representing roughly 30% of all 
neuroendocrine tumors. NETs represent about 3% of all lung cancers. 
Unfortunately, with the exclusion of small-cell lung cancer (SCLC), no large 
phase II and III trials for pulmonary neuroendocrine tumors have been 
published. 
 Neuroendocrine tumors (NETs) of the lung comprise a heterogeneous 
population of tumors ranging from well-differentiated bronchial NETs to 
highly malignant and poorly differentiated small-cell lung cancer (SCLC) 
and large-cell neuroendocrine carcinoma (LCNEC). The incidence of 
pulmonary NETs is low, although reported to have increased over the past 30 
years (Yao JC, et al., 2008) (Skuladottir H, et al.,2002). Typical carcinoids 
(TCs) comprise∼1%–2% and atypical carcinoids (ACs) only 0.1%–0.2% of 
pulmonary neoplasms. According to the surveillance, epidemiology and end 
results program (SEER) database from 2003, the combined incidence has 
been 1.57/100 000 inhabitants ( Gustafsson BI, Kidd M, Chan A et al., 
2008). SCLC is the most common bronchial NET reported to account for 
15%–20% of invasive lung cancers. LCNEC comprise 1.6%–3% of 
resectable lung cancers. The prevalence of thymic NET is∼3% of the total 
number of NETs at all sites. In the last SEER database, a reported incidence 
of thymic NETs is 0.02/100 000 population per year (Gaur P., et al., 2010). 
They constitute∼5% of all thymic tumors. The median age at diagnosis for 
bronchial NETs is 64 years and for thymic NETs 59 years.  
 NETs of the lung include the low-grade TC (well-differentiated), the 
high-grade LCNEC (poorly differentiated) and SCLC. Mixed tumors are 
found in < 5% of patients and are more frequently found in the peripheral 
areas of the lung. About 70% of all bronchial NETs are located in the major 
bronchi and the remainder in the periphery of the lungs. They occur more 
frequently (60%) in the right than in the left lung, and particularly in the 
middle lobe (Travis WD,et al., 1998). The cell of origin for bronchial NETs 
have been suggested to be pulmonary neuroendocrine cells (PNECs) that 
usually exist as solitary cells, but sometimes aggregate to form small nodules 
termed neuroepithelial bodies (NEBs), which are located within the ciliated 
epithelium. PNECs express serotonin and neuron-specific enolase (NSE) and 
also gastrin-releasing peptide (GRP) (Righi L, Volante M, Rapa I et al., 
2007). Up to 90% of patients with central bronchial NETs are symptomatic, 
presenting with hemoptysis, cough, recurrent pulmonary infection, fever, 
chest discomfort and unilateral wheezing, while peripheral carcinoids are 
incidentally discovered in most of the cases (Travis WD,et al., 1998). The 
carcinoid syndrome is very rare in patients with bronchial NETs. 
Nevertheless, a carcinoid crisis may occasionally occur in previously 
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asymptomatic patients following bronchoscopic biopsy laser disobliteration, 
surgical manipulation or peptide receptors radiotherapy (PRRT).  
 
Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes 
Lung and Thymus) 
Adjuvant Therapy 
 There are currently no data to suggest that adjuvant therapy 
(radiation, chemotherapy, or chemoradiation) will prolong a disease-free 
interval or median survival. Therefore, at this time, there are insufficient data 
to recommend the use of adjuvant therapy after complete resection of local-
regional disease (Fukai I, Masaoka A, Fujii Y, et al. 1999) (de Montpreville 
VT, et al., 1996). 
 
Perioperative Treatment of Carcinoid Syndrome 
 Treatment is centered on prevention. Premedication with octreotide, 
such as a single subcutaneous injection of 250 to 500µg, should be a 
sufficient prevention for most minor procedures (Parris WC, et al., 1988). 
Recommend having extra doses available in the operating room or treatment 
area, to be given in 250µg amounts or greater, should the need arise. For 
major procedures, a preoperative intravenosus bolus of 250 to 500 µg, 
followed by a continuous infusion of 100 to 500 µg/h during the procedure, 
has been reported (Weingarten TN, Abel MD, Connolly HM, et al., 2007). 
The infusion is then weaned by 50% daily for a few days until it can be 
safely discontinued and is sometimes supplemented by a dose of long-acting 
depot somatostatin analog. Additional preoperative preparation can include 
short-acting corticosteroids and antihistamines (H1-and H2-blocking agents). 
Hypotension, which is not attributable to acute blood loss, should be treated 
with boluses of octreotide, steroids, and volume expansion. Bronchospasm 
can also be reversed similarly to most allergic reactions with steroids. 
Vasopressors should be avoided because these agents are known to 
potentiate the release of serotonin and vasoactive amines from these tumors. 
Low doses of dopamine, vasopressin, and neosynephrine after pretreatment 
with a high-dose octreotide infusion can effectively prevent perioperative 
precipitation of carcinoid crises (Weingarten TN, Abel MD, Connolly HM, 
et al., 2007).  
 
Treatment of Refractory Carcinoid Syndrome 
 The causes for refractory carcinoid syndrome in NETs, particularly 
refractory diarrhea, include an increase in hormone production by the tumor, 
development of steatorrhea because of pancreatic exocrine insufficiency 
secondary to somatostatin analogs, and development of pellagra because of 
niacin deficiency (Alexandria T. Phan et al., 2010). 
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Somatostatin Analogs 
 The short-acting somatostatin analog is administered initially as a test 
compound to determine safety and tolerability of the long-acting formulation 
and as a rescue injection for periods when the patient is exhibiting severe or 
recalcitrant symptoms. Currently, the long-acting release form of octreotide 
is offered in 10-, 20-, and 30mg formulations, and the currently 
recommended starting dosage is 20 mg/mo. Careful review of the octreotide 
drug registration data reveals that octreotide blood levels are weight 
dependent (Rubin J, et al.,  1999) (Harris AG, et al., 1995).  
 Recent data suggest that up to 40% of patients who are treated with 
the long-acting release formulation may need additional rescue injections of 
short-acting somatostatin at somepoint during their disease course. The need 
for a short-acting rescue medication to optimize symptom management is 
further supported by the data from the registration trial for octreotide long-
acting release. In that trial, 40% of patients required weekly rescue 
medication (regardless of long-acting release dose) and 70% of patients 
required rescue injections at some time during the registration trial. 
 
Interferon alpha 
 Most investigational trials have studied recombinant IFN-α2a or IFN-
α2b. In 30% to 70% of the patients with carcinoid syndrome, symptomatic 
remission with IFN therapy is observed, with a superior effect on flushing 
compared with diarrhea (Wymenga AN, et al., 1998). The effectiveness of 
IFN to control the symptoms of carcinoid syndrome is similar to that of 
somatostatin analogs, but the onset of response is more delayed. In patients 
with the carcinoid syndrome, comparing IFN to somatostatin analog, 
remission or stabilization of tumor markers and/or urinary 5-HIAA excretion 
was observed in 36% to 44% and in 30% to 35%, respectively. In most 
patients, symptoms of flulike syndrome occur during the first 5 days of IFN 
administration. Other common adverse effects include anorexia, weight loss, 
fatigue, and dose-dependent bone marrow toxicity including anemia, 
leucopenia, and thrombocytopenia. Less common adverse effects include 
hepatotoxicity, depression, mental disturbances, and visual impairment (Shah 
T, Caplin M., 2005) (Plockinger U, et al. 2008). The combination of 
octreotide and IFN-α has also been studied. Patients for whom octreotide 
alone produced suboptimal symptom control were included in 3 studies of 
24, 19, and 9 patients (Frank M, et al., 1999). Patients for whom 
monotherapy with IFN had no benefit were also included in 1 of these 
studies (Janson ET, et al., 1992). Biochemical responses were reported in 
77%, 72%, and 75% of patients treated with combination therapy. Results of 
these studies suggest that there may be synergism between somatostatin 
analogs and IFN in controlling symptoms of carcinoid syndrome. 
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Serotonin Receptor Antagonists 
 Serotonin receptor subtype 5-HT1 and 5-HT2 antagonists, such as 
methysergide, cyproheptadine, and ketanserin, and 5-HT3 antagonists, such 
as ondansetron, have also been used in patients with the carcinoid syndrome. 
These drugs generally result in symptomatic improvements of diarrhea and 
nausea but not of flushing (Orbach-Zinger S, et al., 2002). 
 
Anti diarrheal Agents 
 Like in other causes of secretory diarrhea, opiates and loperamide 
have been used for a symptomatic improvement of diarrhea in patients with 
the carcinoid syndrome. 
 
Cushing Syndrome 
 Bronchial and thymic NETs can cause Cushing syndrome because of 
the ectopic production of adrenocorticotropic hormone (ACTH). A bronchial 
NET is the most common cause of ectopic ACTH production. 
 Cushing syndrome could be treated with commonly available agents 
such as ketoconazole, metyrapone, aminoglutethimide, etomidate, mitotane, 
or mifepristone. Ketoconazole is the most popular and effective; it acts on 
several of the P450 enzymes, including the first step in cortisol synthesis, 
cholesterol side-chain cleavage, and conversion of 11-deoxycortisol to 
cortisol. A daily dose of 600 to 800 mg of ketoconazole can effectively 
decrease cortisol production. Adverse effects of ketoconazole include 
headache, sedation, nausea, irregular menses, decreased libido, impotence, 
gynecomastia, and elevated liver function tests. Metyrapone blocks 11-β-
hydroxylase activity, the final step in cortisol synthesis. Therapy with 
metyrapone starts at 1 g/d divided into 4 doses and increases to a maximum 
dose of 4.5 g/d. Adverse effects are secondary to an increase in androgen and 
mineralocorticoid precursors and include hypertension, acne, and hirsutism. 
Aminoglutethimide is an anticonvulsant agent that blocks cholesterol side-
chain cleavage to pregnenolone, with a relatively weak adrenal enzyme 
inhibitor at doses that patients can tolerate. Currently, ami-noglutethimide is 
not commercially available for use. Similar to metyrapone, etomidate, an 
imidazole-derivative anesthetic agent, blocks 11-β-hydroxylase. Its use is 
limited to short-term duration because it has a short half-life and its route of 
administration is intravenous. Etomidate dosage is usually started at 0.3 
mg/kg per hour. Mitotane is an adrenolytic agent that acts by inhibiting 11-β-
hydroxylase and cholesterol side-chain cleavage enzymes. This drug also 
leads to mitochondrial destruction and necrosis of the adrenocortical cells in 
the zona fasciculate and reticularis. For this reason, it is used in the treatment 
of patients with adrenal cortical carcinoma. Mitotane can be used in 
combination with metyrapone. Mitotane is expensive with a very narrow 
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therapeutic index. Adverse effects include moderate gastrointestinal and 
neurologic toxicity: nausea, vomiting, diarrhea, dizziness, and ataxia. 
Another important limitation of mitotane is that it is potentially teratogenic 
and can cause abortion. Mifepristone (RU 486) is an antiprogestational 
agent, which, at high doses, competitively binds to the glucocorticoid and 
progesterone receptors. Although it may be effective, availability and use are 
currently restricted. In some patients, bilateral adrenalectomy may be 
necessary to control for Cushing syndrome when all medical therapy failed. 
For ectopic growth hormone-releasing hormone (GHRH) secretion and 
acromegaly, somatostatin analogs can be of value. Some patients with 
ectopic ACTH syndrome might respond to a somatostatin analog as well 
(Scanagatta P, et al., 2004). 
 Acromegaly from the ectopic production of GHRH is a rare 
manifestation of bronchial NETs. Bronchial NETs are the most common 
cause of extrapituitary GHRH secretion. These patients will likely respond to 
Somatostatin Analog or to surgical debulking (Scheithauer BW, et al., 1984). 
 
Treatment of Advanced Disease 
 The decision to initiate therapy is based on a number of clinical and 
pathological factors including tumor grade, symptoms, performance status, 
and organ functions. Initiation of therapy for progressive disease should be 
considered if patients have symptoms, bulky disease, or evidence of tumor 
growth. Treatment of asymptomatic patients with limited evaluable disease 
and no evidence of progression can also be considered using agents with a 
favorable safety profile such as a somatostatin analog. For patients with 
unresectable disease confined to the liver, liver-directed therapy should be 
considered (Rubin J, et al., 1999). 
 
Somatostatin Analogs 
 Somatostatin analogs have been widely used in NETs for the control 
of hormonal syndromes. Although somatostatin analogs have also been 
frequently used for theoretical cytostatic activity, until recently there were no 
prospective data to support the antiproliferative role of somatostatin analogs. 
In 2009, a somatostatin analog was demonstrated to have an antiproliferative 
activity, where progression-free survival duration of patients with well-
differentiated NETs treated with 30 mg of octreotide long-acting release was 
prolonged compared with those patients who only received placebo (median 
progression-free survival, 14 vs 6 months; hazard ratio, 0.34; 95% 
confidence interval, 0.2-  0.6; P<0.0001) (Rinke A, et al., 2009).  
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Interferon-α 
 Interferon-α has been reported to induce disease stabilization and to 
lead to objective responses in a small number of patients. Most of these 
studies, however, are underpowered. Pooling the data from patients with 
NETs involved in these studies, only 37 (12%) of 309 had objective tumor 
responses (Schnirer II, et al., 2003). 
 Combining somatostatin analogs with IFN can theoretically enhance 
antitumor activity. Two underpowered random assignment studies have 
attempted to compare single-agent and combination therapy. In 1 study, NET 
patients who have undergone debulking by surgery and hepatic artery 
embolization were randomly assigned to octreotide or octreotide plus IFN. A 
significant improvement in time to progression was observed in the IFN arm 
(hazard ratio, 0.28; 95% confidence interval, 0.16-0.45) (Kolby L, et al., 
2003). In a second random assignment trial, patients were treated with 
lanreotide, IFN or lanreotide plus IFN. Objective response rates were 4%, 
4%, and 7%, respectively (Faiss S, et al., 2003). Although there is no defined 
standard therapy for NET patients with progressive disease, somatostatin 
analog plus IFN can be considered as an accepted option. 
 
Chemotherapy 
 For metastatic well-differentiated NETs as a group, multiple 
cytotoxic drugs have been tried in various combinations; however, 
randomized trials have revealed only minor activity. As a result, there is no 
standard regimen, and the role of chemotherapy for advanced well-
differentiated NETs, in general, continues to be debated. Patients with 
foregut NETs such as those originating from the lung and thymus may derive 
some benefit from cytotoxic chemotherapy. Results from a published phase 2 
study suggest antitumor activity with singleagent temozolomide for well-
differentiated NETs, particularly those with foregut NETs. Patients with 
metastatic or inoperable advanced NETs included 13 bronchial NETs (10 
typical and 3 atypical); all received oral temozolomide for 5 consecutive 
days every 28 days (Ekeblad S, et al., 2007). Four (31%) had a partial 
response, whereas 4 others (31%) had stable disease. The limited efficacy of 
chemotherapy has prompted investigation of novel therapeutic approaches 
for patients with advanced NETs. These include targeted radiotherapy (eg, 
therapeutic131I-MIBG, lutetium Lu 177 octreotate), inhibitors of 
angiogenesis (eg, bevacizumab), small molecule tyrosine kinase inhibitors 
(eg, sunitinib), and mammalian target of rapamyacin small molecule 
inhibitor (eg, everolimus). These novel treatments, although demonstrating 
promising efficacy in clinical studies, are still considered investigational 
therapy and are currently only available to patients on clinical trials. 
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Liver-Directed Therapy 
 Many patients with NETs have extensive liver involvement and may 
require regional liver therapy. Regional arterial therapies are administered 
through angiographic catheters and can be delivered in a segmental, lobar, or 
whole liver distribution. These include bland embolization, 
chemoembolization, radioactive microsphere embolization, and percutaneous 
hepatic perfusion. Particle embolization with or without chemotherapy has 
long been the standard therapy for NET patients with extensive liver 
involvement (Pommier RF, et al., 1996) (Gupta S, et al., 2005).  Patients can 
frequently develop postembolization syndrome (fever, pain, nausea, and 
vomiting), requiring a short stay in the hospital. Prospective randomized 
controlled comparison of hepatic artery embolization and 
chemoembolization is lacking. Therefore, the question of whether hepatic 
chemoembolization is better than hepatic bland embolization for patients 
with NETs remains unresolved. In recent years, radioactive microsphere 
embolization is emerging as a well-tolerated outpatient procedure, providing 
symptom relief and encouraging response rates (Kennedy AS, et al., 2008). 
Preliminary data with percutaneous hepatic perfu- sion using melphalan in 
patients with NETs are also encouraging. Regional treatments have also been 
used to convert patients with unresectable to resectable disease; the 
frequency of conversion remains rare. 
 These nonsurgical therapies are reserved for patients who have no 
surgical options. A multidisciplinary team approach to formulate individual 
therapy specific and optimal for each NET patient consisting of surgical 
and/or nonsurgical treatment is highly recommended. Often, hepatic tumor 
burden can be safely cytoreduced using a multispecialty approach involving 
experienced interventional radiologists, hepatobiliary surgeons, and medical 
oncologists. Even in the setting of unresectable disease, patients with NETs 
should be periodically assessed for disease status (stable or progressive 
disease) and surgical candidacy. 
 
Follow-Up of Patients with Thymic and Bronchial NETs  
 General guidelines consist of identifying any disease-related 
symptom(s), biochemical markers (specific and nonspecific), and imaging 
assessment to determine the precise tumor localization and possible 
metastases by CT or MRI and [111In-DTPA0]octreotide scintig- raphy 
(Octreoscan). After surgery, patients are typically reevaluated 3 months 
postoperatively to establish a new ‘baseline’. The term ‘as clinically 
indicated’ refers to changes of symptoms or signs from baseline, rising tumor 
marker(s), and CT/MRI changes suggestive of tumor growth. Tumor markers 
to consider are dependent on the primary NET site. Serum CgA is the most 
sensitive but the least specific, whereas urine 5-HIAA is the most specific 
European Scientific Journal August 2015 edition vol.11, No.24  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
338 
but not sensitive for diagnosing early disease. Serotonin is recognized as a 
variable and labile tumor marker when followed serially, but it may be useful 
in making a diagnosis. Elevated or abnormal 24-hour urinary 5-HIAA level 
has a sensitivity of 75% and a specificity of up to 100% in making a 
diagnosis of thymic or bronchial NET (Feldman JM., 1986). This test may 
help to confirm the diagnosis, it is fraught with human errors that may be 
induced by certain drugs or activities. In fact, thymic or bronchial NET cells 
often lack aromatic amino acid decarboxylase, which is necessary to convert 
tryptophan to serotonin and ultimately to urine 5-HIAA. Thus, in patients 
with thymic or bronchial NETs, measurement for urine 5-HIAA is not as 
helpful or as useful as urinary serotonin. Triple-phase helical CT and MRI 
are the preferred imaging modality when hepatic tumor infiltration is present 
or strongly suspected. For NET patients with contrast allergy, MRI 
(enhanced and unenhanced) is recommended. Ultimately, for patients unable 
to undergo CT or MRI, serial [111In-DTPA0]octreotide scintigraphy 
(Octreoscan) is suggested. Although no prospective study has been attempted 
to demonstrate the utility of any specific follow-up protocol, it is accepted 
that after curative resection, an active surveillance program can detect early 
tumor relapse. The toretically, early detection of tumor recurrence or relapse 
can lead to an improved chance of achieving complete resection and allow 
for early initiation of therapy. Because of the indolent nature of well-
differentiated NETs, patients need not be followed up at short intervals, but 
they can be followed up with long-intervening periods. Recommend that 
patients with NETs be reassessed once between 3 and 6 months after 
complete curative resection. Subsequently, patients should be evaluated 
every 6 to 12 months for at least 7 years after curative surgical resection. 
Follow-up evaluation should consist of interval history, physical 
examination, and laboratory testing including CgA and 5-HIAA at a 
minimum.  
 Among patients undergoing surveillance after complete resection, we 
recommend cross-sectional imaging (CT) of the soft tissues of the head and 
neck and the chest and periodic (every 6-12 months) cross-sectional imaging 
(CT or MRI) of the abdomen and pelvis. The role of routine [11I1n-
DTPA0]octreotide scintigraphy (Octreoscan) has not been defined by 
prospective studies. Many experts, however, would advocate the use of 
[111In-DTPA0]octreotide scintigraphy (Octreoscan) yearly as follow-up for 
patients without evidence of disease or on an as-needed basis to define 
indeterminate radiologic findings. For patients with advanced disease, we 
generally recommend the use of cross-sectional imaging for known sites of 
disease. [111In-DTPA0]octreotide scintigraphy (Octreoscan) can be used to 
test in vivo for the presence of somatostatin receptors 2 and 5. It can also be 
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used to evaluate if peptide receptor radiotherapy represents a reasonable 
treatment option (Alexandria T. et al., 2010).  
 
Poorly Differentiated Neuroendocrine Tumors/Large or Small Cell 
Tumors 
 Primary Treatment of Poorly Differentiated/Large or Small Cell 
Tumors (chemotherapy with a small cell lung cancer regimen with or 
without radiotherapy). 
 For resectable poorly differentiated/small cell tumors, surgical 
resection and chemotherapy with a small cell lung cancer regimen with or 
without radiotherapy are advised. In general, cisplatin or carboplatin and 
etoposide are recommended as primary treatment.  
 Envolving data suggest that patients with intermediate Ki-67 levels 
(in the 20%–50% range) may not respond as well to platinum/etoposide as 
patients with small cell histology or those with extremely high Ki-67. 
Clinical judgement should be used in selecting chemotherapy regimens for 
patients with Ki-67 levels in this intermediate range (NCCN Guidelines 
Version 2., 2014 ). 
 
Treatment of loco-regional disease (limited disease) 
 Poorly differentiated NECAs are characterized by a high proclivity 
for metastatic dissemination even in patients with clinically localized tumors. 
This principle is validated by retrospective studies confirming that surgery 
alone is rarely curative (Casas F, et al., 1997) (Brenner B, et al.,  2004). 
Based on the treatment paradigm for limited-stage small-cell lung cancer, a 
course of definitive chemotherapy (cisplatin or carboplatin and etoposide for 
4-6 cycles) and radiation can be considered in many patients with loco-
regional extrapulmonary PD (poorly differentiate) NECAs (neuroendocrine 
carcinoma), particularly when surgical resection is difficult. Clinical trials in 
small-cell lung cancer suggest that concurrent chemoradiation is more 
efficacious than sequential treatment but at the expense of increased toxicity 
(Takada M, et al., 2002). The optimal sequencing of chemotherapy with 
radiation in extrapulmonary PD NECA is unknown. Likewise, the benefit of 
surgery among patients who have completed a course of chemoradiation is 
uncertain. Whereas there are no studies examining adjuvant postoperative 
treatment in PD NECAs, their aggressive behavior warrants consideration of 
adjuvant therapy in most cases. Chemotherapy (4-6 cycles of cisplatin or 
carboplatin and etoposide) is recommended. Sequential radiation can also be 
considered in cases where the risk of local recurrence is thought to be higher 
than average (eg, carcinomas of the rectum or cervix).  
 The incidence of brain micrometastases in small-cell lung cancer is 
high, necessitating prophylactic cranial irradiation for patients with 
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successfully treated limited-stage disease (Meert AP, al., 2001). Data on 
extrapulmonary PD NECAs suggest a lower frequency of central nervous 
system metastases (Cicin I, et al., 2007). Consequently, routine prophylactic 
cranial irradiation cannot be recommended in this population but may be 
considered among patients with PD NECAs of the head and neck or 
unknown primary site. 
 
Treatment of metastatic disease (extensive disease) 
 Based on the established role of cisplatin and etoposide in metastatic 
small-cell lung cancer, this combination has been investigated in metastatic 
NECAs of the GI tract. The first such study explored infusional cisplatin and 
etoposide among 45 patients with metastatic NECAs, of whom 18 had PD 
tumors. A response rate of 67% was reported in patients with PD NECAs, 
with response duration of 8 months and a median survival of 19 months 
(Moertel CG, et al., 1991). A subsequent study of 53 patients with PD 
NECAs of the GI tract treated with a bolus regimen of cisplatin and 
etoposide reported a response rate of 42% with response duration of 9 
months and a median survival of 15 months (Mitry E, et al., 1999). Based on 
these studies, the combination of cisplatin and etoposide is recommended as 
first-line therapy for metastatic PD NECAs. Alternative regimens 
substituting carboplatin for cisplatin (Lassen U, et al., 1996) or irinotecan for 
etoposide (Hanna N, et al., 2006) have been validated in metastatic small-cell 
lung cancer and are therefore thought to be acceptable options for 
management of extrapulmonary PD NECAs. The optimal duration of 
chemotherapy has not been clearly defined, and it remains unclear whether 
treatment beyond 4 cycles is associated with a survival benefit. There are no 
studies of salvage chemotherapy in extrapulmonary PD NECAs. Second-line 
chemotherapy regimens in refractory or relapsed small-cell lung cancer are 
typically associated with modest response rates of 0% to 20%. One study 
ooral topotecan versus supportive care in relapsed small-cell lung cancer 
demonstrated a 3-month improvement in median survival (O’Brien ME, et 
al., 2006). 
 Based on this data, topotecan can be recommended as a salvage 
option for relapsed PD NECAs. Alternatively, retreatment with a platinum 
and etoposide or irinotecan regimen can be considered in patients who 
relapse more than 3 to 6 months after termination of first-line chemotherapy. 
Other agents with similar reported activity in small-cell lung cancer include 
paclitaxel, docetaxel, vinorelbine, and gemcitabine (Walenkamp AM, et al., 
2009). 
 Octreotide therapy can be considered for symptom control in the rare 
cases of hormone-secreting tumors that are unresectable or metastatic. 
Lanreotide, which is approved for symptom control in Europe, has a similar 
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mechanism of action as octreotide. Because it is injected subcutaneously, it 
may be preferable in patients who have difficulty tolerating an intramuscular 
injection. 
 
Follow-Up of Patients with Poorly Differentiated/Large or Small Cell 
Tumors  
 After surgery, surveillance consists of a routine H&P along with 
appropriate imaging studies every 3 months for the first year and every 6 
months thereafter. Patients with locoregional, unresectable disease and with 
metastatic disease should be monitored at least every 3 months (NCCN 
Guidelines Version 2., 2014 ).  
 
Summary: 
 NETs of the lung comprise a heterogeneous population of tumors 
ranging from well-differentiated bronchial NETs to highly malignant and 
poorly differentiated small-cell lung cancer and large-cell neuroendocrine 
carcinoma. The improvement in histological diagnostic tools, including 
neuroendocrine markers by immunohistochemistry, has led to an increased 
recognition of pulmonary neuroendocrine tumors. No large phase II and III 
trials for pulmonary neuroendocrine tumors have been published. Several 
treatment approaches are available for their treatment but none of them has 
been validated in appropriately designed and adequately sized clinical trials. 
The main problem of the published studies is that they include    
neuroendocrine tumors from various sites of origin with different clinical 
behavior. 
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